Kazia Therapeutics (KZIA) Debt to Equity (2018 - 2025)
Kazia Therapeutics' Debt to Equity history spans 5 years, with the latest figure at -$0.05 for Q2 2025.
- For Q2 2025, Debt to Equity rose 92.62% year-over-year to -$0.05; the TTM value through Jun 2025 reached -$0.05, up 92.62%, while the annual FY2025 figure was -$0.05, 92.62% up from the prior year.
- Debt to Equity reached -$0.05 in Q2 2025 per KZIA's latest filing, up from -$0.65 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.71 in Q2 2023 to a low of -$0.65 in Q2 2024.
- Average Debt to Equity over 4 years is -$0.02, with a median of -$0.07 recorded in 2025.
- Peak YoY movement for Debt to Equity: surged 808.34% in 2023, then plummeted 190.62% in 2024.
- A 4-year view of Debt to Equity shows it stood at -$0.1 in 2022, then soared by 808.34% to $0.71 in 2023, then tumbled by 190.62% to -$0.65 in 2024, then soared by 92.62% to -$0.05 in 2025.
- Per Business Quant, the three most recent readings for KZIA's Debt to Equity are -$0.05 (Q2 2025), -$0.65 (Q2 2024), and $0.71 (Q2 2023).